- Home
- BMEZ vs PHAT Comparison
BMEZ vs PHAT Comparison
Compare BMEZ & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BMEZ | PHAT |
|---|---|---|
| Founded | N/A | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 936.9M | 894.0M |
| IPO Year | 2019 | 2019 |
Fundamental Metrics
Financial Performance| Metric | BMEZ | PHAT |
|---|---|---|
| Price | $14.90 | $11.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $19.50 |
| AVG Volume (30 Days) | 240.9K | ★ 942.7K |
| Earning Date | 01-01-0001 | 05-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 42.72 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $175,110,000.00 |
| Revenue This Year | N/A | $83.18 |
| Revenue Next Year | N/A | $61.43 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 216.93 |
| 52 Week Low | $12.58 | $2.21 |
| 52 Week High | $15.80 | $18.31 |
Technical Indicators
Market Signals| Indicator | BMEZ | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 43.68 | 37.56 |
| Support Level | $14.85 | $10.65 |
| Resistance Level | $15.10 | $11.19 |
| Average True Range (ATR) | 0.18 | 0.89 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 53.20 | 11.13 |
Price Performance
Historical ComparisonAbout BMEZ BlackRock Health Sciences Term Trust of Beneficial Interest
BlackRock Health Sciences Trust II is a closed-ended management investment company. The investment objective is to provide total return through a combination of current income and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities of energy and natural resources companies and equity derivatives with exposure to the energy and natural resources industry.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.